In MS patients, fingolimod treatment reduced circulating TJ proteins, including Cldn5, which was associated with fewer new brain lesions, suggesting stabilization of the BBB via inhibition of TJ protein shedding and immune cell trafficking [69]. Here, CLDN5 is linked to myeloid sarcoma.